Saturday, 31 October 2026European Markets

PEXIP HOLDING Stock Was Up By 10.07% On Tuesday

Loading stream...

(VIANEWS) - The Market ended the session with PEXIP HOLDING (PEXIP.OL) rising 10.07% to kr28.20 on Tuesday, after two successive sessions in a row of losses. Oslo Børs Benchmark Index_GI rose 0.19% to kr1,302.94, after two consecutive sessions in a row of gains, on what was a somewhat positive trend trading session today.

PEXIP HOLDING's last close was kr25.62, 11.59% under its 52-week high of kr28.98.

About PEXIP HOLDING

Pexip Holding ASA, a video technology company, provides end-to-end video conferencing platform and digital infrastructure worldwide. The company offers self-hosted software application and as-a-service deployment options for enterprise video conferencing, built on its proprietary Infinity technology. Its interoperability solutions are integrated into Microsoft Teams, Skype for Business, and Google Hangouts. The company serves government, healthcare, education, finance, legal, judicial, and retail industries. Pexip Holding ASA was founded in 2011 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, PEXIP HOLDING has a trailing twelve months EPS of kr-0.83.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -5.06%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

PEXIP HOLDING's EBITDA is 613.17.

Moving Average

PEXIP HOLDING's worth is higher than its 50-day moving average of kr26.12 and way above its 200-day moving average of kr22.16.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, PEXIP HOLDING's stock is considered to be overbought (>=80).

More news about PEXIP HOLDING (PEXIP.OL).

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com